Here is the medical news to watch for April 14-20, 2025

The PainConnect meeting, sponsored by the American Academy of Pain Medicine (AAPM), offered an opportunity to learn more about the outlook for a newly approved non-opioid (Vertex's Journavx) and two new pain medications in development -- Tris Pharma's cebranopadol and Tonix Pharmaceuticals' TNX-102 SL.

March was a busy month for the European Society for Medical Oncology (ESMO), with two major conferences in Paris: the ESMO Targeted Anticancer Therapies (TAT) Congress and the European Lung Cancer Congress (ELCC). Neither meeting was virtual, but ESMO arranged two zoom sessions with reporters. Here are some highlights from those sessions.

Drug development is alive and well in dermatology, and among the interesting data on new drugs/new uses for existing drugs presented in a latebreaker session at AAD this year were:
• Alumis’ ESK-001, a TYK2 inhibitor for psoriasis.
• Johnson & Johnson/Janssen Biotech and Protagonist Therapeutics’ icotrokinra, an oral IL-23R inhibitor for psoriasis.
• Jasper Therapeutics’ briquilimab, an anti-CD117 for chronic spontaneous urticaria.

Dermatology continues to be a hot area for drug development – both new drugs and new uses for existing drugs. Among the studies that stood out this year at AAD were:
• Leo Pharma’s Anzupgo (delgocitinib), a JAK inhibitor in hand eczema
• Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab), an anti-IL-4R in bullous pemphigoid
• Bristol Myers Squibb’s Sotyktu (deucravacitinib), a TYK2 inhibitor for lichen planopilaris
• Lilly’s Olumiant (baricitinib), a JAK inhibitor for adolescent alopecia areata

This conference offered a great update on 13 different drugs, both approved and in development, to treat dry AMD, geography atrophy, wet AMD, and DME.

2025 Medical Calendar - 2nd Half

Here are some of the things we found interesting in the posters at ASCO-GI